ESTRO 2023 - Abstract Book

S1052

Digital Posters

ESTRO 2023

Of all the twenty clinical trials, One Danish trial selected patients when standard planning showed a mean heart dose of 4 Gray (Gy) or more and/or a Volume lung that received 20 Gy lung (V20) of 37% or more. One MD Anderson's trial adaptive randomized selected patients to receive proton or photon planning only if both plans met dosimetric limitations. All patients who met the general radiation requirement would be randomized (14/20) or non-randomized (2/20) to each arm. The other trials are four (4/20) prospective cohorts. The patients' median age for five publications ranged from 66-76 years. Seven toxicity endpoints could be pooled (four papers on Non-Small Cell Lung Cancer (NSCLC) and one paper on Esophageal Cancer). No survival data could be pooled. The relative risk (RR) and the 95% confidence interval (CI) of several common toxicities are: Grade ≥ 3 pneumonitis (1.25(0.48 3.23)), Grade ≥ 3 esophagitis (0.94(0.37-2.39)), Grade ≥ 2 dermatitis (2.00(0.18-22.06)). There was no difference in any endpoint. Eighteen first endpoints from the fifteen ongoing clinical trials are summarized, including NSCLC (three endpoints on the lung/total toxicity, three on the Overall Survival(OS)/Progression-free Survival (PFS), and one on failure pattern), Breast Cancer (five on heart/vessels toxicity, two on cosmesis, and one on dose-volume analyses), and Esophageal Cancer (two on lung/cardiopulmonary function, and one on OS). Except for the Danish trial, no other ongoing trials (14/15) have particular patient selection criteria.

Conclusion This systematic review suggests that proton therapy has no added value when given to unselected patients. However, only one ongoing study includes high-risk patients for toxicity.

PO-1312 Stereotactic Body Radiation Therapy (SBRT) for Oligometastatic Lung metastasis

A. Gawish 1 , B. Röllich 1 , M. Ha 1 , T. Brunner 2

1 University Hospital Magdeburg, Department of Radiation Oncology, Magdeburg, Germany; 2 University Hospital Graz, Department of Radiation Oncology, Graz, Austria Purpose or Objective The role of stereotactic body radiation therapy in treating inoperable pulmonary is still unclear, although it represents a non-invasive, efficacious option. We report the outcomes of patients treated with SBRT in cases of pulmonary oligometastatic disease. Materials and Methods We conducted a retrospective analysis of patients treated with SBRT for the oligometastatic pulmonary metastasis at our department. We examined the relationship between various patient and therapy characteristics and local failure (LF), progression, following treatment, systemic treatment, and overall survival (OS) using univariate and multivariate analyses.